Claims for Patent: 10,940,142

Summary for Patent: 10,940,142

Title:	Inhibition of crystal growth of roflumilast
Abstract:	Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
Inventor(s):	Osborne; David W. (Fort Collins, CO)
Assignee:	Arcutis, Inc. (Menlo Park, CA)
Application Number:	16/136,804
Patent Claims:	1. A pharmaceutical composition comprising roflumilast, hexylene glycol, cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate. 2. The pharmaceutical composition according to claim 1, wherein said hexylene glycol is in an amount sufficient to inhibit roflumilast crystal growth or changes in particle size. 3. The pharmaceutical composition according to claim 1, wherein said hexylene glycol is in an amount of 0.1-20% w/w. 4. The pharmaceutical composition according to claim 1, wherein said roflumilast is in an amount of 0.005-2% w/w. 5. The pharmaceutical composition according to claim 1, wherein said composition comprises 0.005-0.5% roflumilast. 6. The pharmaceutical composition according to claim 1, wherein said composition comprises carriers suitable for topical, parenteral or pulmonary administration. 7. The pharmaceutical composition according to claim 6, wherein said pharmaceutical composition comprises carriers suitable for topical administration. 8. A pharmaceutical composition comprising roflumilast, hexylene glycol and a pharmaceutically acceptable solvent. 9. The pharmaceutical composition according to claim 8, wherein said pharmaceutically acceptable solvent is water. 10. The pharmaceutical composition according to claim 8, wherein said roflumilast is near saturation. 11. The pharmaceutical composition according to claim 8, further comprising an additional active agent selected from the group consisting of Anthralin, Azathioprine, Tacrolimus, Coal tar, Methotrexate, Methoxsalen, Salicylic acid, Ammonium lactate, Urea, Hydroxyurea, 5-fluorouracil, Propylthouracil, 6-thioguanine, Sulfasalazine, Mycophenolate mofetil, Fumaric acid esters, Corticosteroids, Corticotropin, Vitamin D analogues, Acitretin, Tazarotene, Cyclosporine, Resorcinol, Colchicine, Adalimumab, Ustekinumab, Infliximab, bronchodialators, and antibiotics. 12. A pharmaceutical composition comprising roflumilast, hexylene glycol, and an emulsifier. 13. The pharmaceutical composition according to claim 12, wherein said emulsifier is in an amount of 10% w/w. 14. The pharmaceutical composition according to claim 13, wherein said emulsifier is a blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate.